<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1561-3194</journal-id>
<journal-title><![CDATA[Revista de Ciencias Médicas de Pinar del Río]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Ciencias Médicas]]></abbrev-journal-title>
<issn>1561-3194</issn>
<publisher>
<publisher-name><![CDATA[Editorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1561-31942024000200023</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Articulo revisión]]></article-title>
<article-title xml:lang="en"><![CDATA[Update on the genetic basis and therapeutic perspectives in X-linked Agammaglobulinemia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Pacheco]]></surname>
<given-names><![CDATA[Julio Israel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lorenzo-Rodríguez]]></surname>
<given-names><![CDATA[Michel Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leiva-Pantoja]]></surname>
<given-names><![CDATA[Enoy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Pinar del Río. Hospital Pediátrico Provincial Docente &#8220;Pepe Portilla&#8221; Pinar de Río ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Guayaquil,  ]]></institution>
<addr-line><![CDATA[Ecuador ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2024</year>
</pub-date>
<volume>28</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1561-31942024000200023&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1561-31942024000200023&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1561-31942024000200023&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  las inmunodeficiencias primarias constituyen un grupo de enfermedades de base genética debido a alteraciones cuantitativas o funcionales de distintos mecanismos implicados en la respuesta inmunológica. De acuerdo a su patrón de herencia pueden ser autosómicas dominantes y recesivas o ligadas al X.  Objetivo:  describir las bases genéticas y las perspectivas terapéuticas de la Agammaglobulinemia ligada al X.  Métodos:  se realizó una revisión de la literatura mediante una búsqueda de información en las bases de datos Medline/PubMed, Bireme (Scielo, Lilacs) y la biblioteca médica Cochrane en los meses de octubre y noviembre de 2023. Se empleó una fórmula de búsqueda avanzada.  Desarrollo:  en la actualidad se han descrito más de 350 inmunodeficiencias primarias, de las cuales en más de 250 se ha mapeado el gen responsable y se sospecha que unos 3000 genes podrían estar relacionados con su origen. La Agammaglobulinemia ligada al X resulta de la pérdida de variantes de función en el gen de la tirosina quinasa de Bruton con locus génico en el brazo largo del cromosoma X en el que se han descrito más de 700 mutaciones exónicas e intrónicas.  Conclusiones:  la complejidad del diagnóstico molecular de estos trastornos radica en el hecho de la gran heterogeneidad genética que presentan. La terapia de reemplazo de inmunoglobulinas sigue siendo la principal herramienta terapéutica. La edición genética constituye un promisorio enfoque para tratar la Agammaglobulinemia ligada al X y los errores innatos de la inmunidad en sentido general.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: primary immunodeficiencies constitute a group of diseases with a genetic basis due to quantitative or functional alterations of different mechanisms involved in the immune response. According to their inheritance pattern they can be autosomal dominant and recessive or X-linked.  Objective: to describe the genetic basis and therapeutic perspectives of X-linked agammaglobulinemia. Methods: A literature review was performed by searching the Medline/PubMed, Bireme (Scielo, Lilacs) and Cochrane Medical Library databases in October and November 2023 using an advanced search formula.  Development: currently more than 350 primary immunodeficiencies have been described, of which more than 250 have been mapped with the responsible gene and it is suspected that about 3000 genes could be related to their origin. X-linked agammaglobulinemia results from loss of function variants in the Bruton's tyrosine kinase gene with gene locus on the long arm of the X chromosome in which more than 700 exonic and intronic mutations have been described.  Conclusions: the complexity of the molecular diagnosis of these disorders lies in the fact of the great genetic heterogeneity they present. Immunoglobulin replacement therapy remains the main therapeutic tool. Gene editing is a promising approach to treat X-linked agammaglobulinemia and inborn errors of immunity in general.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[AGAMMAGLOBULINEMIA]]></kwd>
<kwd lng="es"><![CDATA[CROMOSOMA X]]></kwd>
<kwd lng="es"><![CDATA[ENFERMEDADES DE INMUNODEFICIENCIA PRIMARIA]]></kwd>
<kwd lng="es"><![CDATA[ENFERMEDADES DEL SISTEMA INMUNE.]]></kwd>
<kwd lng="en"><![CDATA[AGAMMABLOBULINEMIA]]></kwd>
<kwd lng="en"><![CDATA[X CHROMOSOME]]></kwd>
<kwd lng="en"><![CDATA[PRIMARY IMMUNODEFICIENCY DISEASES]]></kwd>
<kwd lng="en"><![CDATA[IMMUNE SYSTEM DISEASES]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matos]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Inocente]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Córdova]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Aldave]]></surname>
<given-names><![CDATA[BJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico genético de pacientes con AgammaGlobulinemia primaria atendidos en Centros Peruanos de Tercer Nivel.]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Pública]]></source>
<year>2019</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>664-9.</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Candelaria]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés]]></surname>
<given-names><![CDATA[LL.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunodeficiencias primarias: un reto para la inmunogenética.]]></article-title>
<source><![CDATA[Rev Cuba Reumatol]]></source>
<year>2020</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Modell]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Orange]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Modell]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Growth in diagnosis and treatment of primary immunodeficiency within the global Jeffrey Modell Centers Network.]]></article-title>
<source><![CDATA[Allergy Asthma Clin Immunol]]></source>
<year>2022</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meyts]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bousfiha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Duff]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Condino-Neto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary immunodeficiencies: A decade of progress and a promising future.]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2021</year>
<volume>11</volume>
<page-range>625753</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tangye]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Herz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Bousfiha]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human inborn errors of immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2022</year>
<volume>42</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1473-1507.</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leonardi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rivalta]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cancrini]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update in primary immunodeficiencies.]]></article-title>
<source><![CDATA[Acta Biomed]]></source>
<year>2020</year>
<volume>91</volume>
<numero>11-S</numero>
<issue>11-S</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abolhassani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Azizi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sharifi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yazdani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mohsenzadegan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Delavari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global systematic review of primary immunodeficiency registries.]]></article-title>
<source><![CDATA[Expert Rev Clin Immunol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>717-732.</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chinn]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma and Immunology.]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2020</year>
<volume>145</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-69.</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cárdenas]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[TVP.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Agammaglobulinemia: from X-linked to autosomal forms of disease.]]></article-title>
<source><![CDATA[Clin Rev Allergy Inmunol]]></source>
<year>2022</year>
<volume>63</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-35.</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jo]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kanegane]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Futatani]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hwa]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Kyu]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangement resulting in large deletion, in Korean X-linked agammaglobulinemia patients.]]></article-title>
<source><![CDATA[J Hum Genet]]></source>
<year>2003</year>
<volume>48</volume>
<page-range>322-326.</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Da Silva]]></surname>
<given-names><![CDATA[RFJ]]></given-names>
</name>
<name>
<surname><![CDATA[Loss de Morais]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Biso de Carvalho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[dos Santos]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Lehmkuhl]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Guimaraes]]></surname>
<given-names><![CDATA[APC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and genetic findings in two siblings with X-Linked agammaglobulinemia and bronchiolitis obliterans: a case report.]]></article-title>
<source><![CDATA[BMC Pediatr]]></source>
<year>2022</year>
<volume>22</volume>
<page-range>181</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vihinen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mattsson]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[CI.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bruton tyrosine Kinase (BTK) in X-linked agammaglobulimemia (XLA).]]></article-title>
<source><![CDATA[Front Biosci]]></source>
<year>2000</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>17-28.</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rawat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jindal]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Suri]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vignesh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Saikia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perfil clínico y genético de la agammaglobulinemia ligada al cromosoma X: una experiencia multicéntrica de la India. Frente.]]></article-title>
<source><![CDATA[Immunol]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>612323</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="">
<source><![CDATA[The Human Gene Mutation Database]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chua]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
<name>
<surname><![CDATA[Mondragon]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen-Ngoc-Quynh]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Imai]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectivas actuales y necesidades insatisfechas de la atención primaria de inmunodeficiencia en Asia Pacífico. Frente]]></article-title>
<source><![CDATA[Immunol]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>1605</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[RMC]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Cambronero]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrerira]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Fontán]]></surname>
<given-names><![CDATA[CG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico molecular de inmunodeficiencias primarias.]]></article-title>
<source><![CDATA[Allergol Inmunophatol]]></source>
<year>2001</year>
<volume>29</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>107-113.</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shillitoe]]></surname>
<given-names><![CDATA[BMJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gennery]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización sobre la agammaglobulinemia ligada al cromosoma X: manifestaciones clínicas y tratamiento]]></article-title>
<source><![CDATA[Curr Opin Allergy Clin Immunol]]></source>
<year>2019</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>571-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="book">
<source><![CDATA[Diagnóstico y tratamiento de las inmunodeficiencias primarias.]]></source>
<year>2023</year>
<publisher-name><![CDATA[Mayo Clínica.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment for X-linked Agammaglobulinemia with allogeneic umbilical cord blood stem cell transplantation from HLA- matched sibling confirmed healthy through Prenatal Diagnosis.]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2018</year>
<volume>132</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Heimall]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Greenhawt]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bunin]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shaker]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Romberg]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost utility of lifelong immunoglobulin replacement therapy vs hematopoietic stem cell transplant to treat Agammaglobulinemia.]]></article-title>
<source><![CDATA[JAMA Pediatr]]></source>
<year>2022</year>
<volume>176</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>176-184.</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[SSG]]></given-names>
</name>
<name>
<surname><![CDATA[Condino]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of patients with immunodeficiency: Medication, gene therapy, and transplantation.]]></article-title>
<source><![CDATA[J. Pediatr]]></source>
<year>2021</year>
<volume>97</volume>
<numero>^ssuppl 1</numero>
<issue>^ssuppl 1</issue>
<supplement>suppl 1</supplement>
</nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[El largo y sinuoso camino hacia una terapia génica CRISPR para la agammaglobulinemia ligada al cromosoma X]]></source>
<year>2022</year>
<publisher-name><![CDATA[Medicina CRISPR]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Keir]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Abele]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing integration and expression of transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X- Linked Agammaglobulinemia.]]></article-title>
<source><![CDATA[CRISPR J]]></source>
<year>2021</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>191-206.</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[li]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in CRISPR/Cas gene therapy for inborn errors of immunity.]]></article-title>
<source><![CDATA[Front Inmunol]]></source>
<year>2023</year>
<volume>14</volume>
<page-range>1111777</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
